← Back to Search

Visual confusion for Binocular Fusion Defect

N/A
Waitlist Available
Led By JaeHyun Jung
Research Sponsored by Massachusetts Eye and Ear Infirmary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 1-2 sessions to finish total 6 trials, up to 2 hours for each session, any time within the 4month study period
Awards & highlights

Summary

This trial will help researchers understand how our brain processes information from what we see.

Eligible Conditions
  • Binocular Fusion Defect
  • Monocular Double Vision
  • Binocular Vision Suppression
  • Double Vision

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 1-2 sessions to finish total 6 trials, up to 2 hours for each session, any time within the 4month study period
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 1-2 sessions to finish total 6 trials, up to 2 hours for each session, any time within the 4month study period for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Total Viewing Time That Peripheral Target is Perceived

Trial Design

1Treatment groups
Experimental Treatment
Group I: Visual confusionExperimental Treatment3 Interventions
Participants viewed peripheral targets in three different visual confusion conditions (three interventions): binocular visual confusion (unilateral opaque target), unilateral monocular visual confusion (unilateral see-through target), and bilateral monocular visual confusion (bilateral see-through target). Each intervention was presented twice in a randomized order, resulting in a total of six trials. During each trial, a peripheral target was presented in front of a forward-moving background for one minute. Participants were instructed to hold down the controller button while the target was visible and release it when a third or more of the target disappeared. After each trial, participants could take a brief break before the next trial in a different visual confusion condition was presented in a randomized order.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bilateral monocular visual confusion (bilateral see-through)
2021
N/A
~20
Unilateral monocular visual confusion (unilateral see-through)
2021
N/A
~20
Binocular visual confusion (unilateral opaque)
2021
N/A
~20

Find a Location

Who is running the clinical trial?

National Eye Institute (NEI)NIH
548 Previous Clinical Trials
1,401,862 Total Patients Enrolled
Massachusetts Eye and Ear InfirmaryLead Sponsor
107 Previous Clinical Trials
12,973 Total Patients Enrolled
JaeHyun JungPrincipal InvestigatorSchepens Eye Research Institute
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top